BioNTech's ASCO Reckoning: Pumitamig Takes on Pembrolizumab Amid Restructuring and CEO Exit
21.05.2026 - 16:12:43 | boerse-global.de
The clock is ticking for BioNTech. As the embargo lifts on more than 7,000 study abstracts for the ASCO cancer conference, the biotech's stock sits at €77.65 — a full 24% below its yearly high and well under the 200-day moving average. Investors are holding their breath for a single drug to prove that the Mainz-based company can truly pivot from pandemic hero to oncology powerhouse.
Pumitamig, the bispecific antibody at the center of the transformation, will square off against the established frontline standard for non-small cell lung cancer. The Phase 2 ROSETTA Lung-02 study pits pumitamig plus chemotherapy directly against pembrolizumab in a head-to-head comparison — a high-stakes wager that leaves little room for ambiguity. The Phase 3 portion of the trial is already enrolling patients, but the data released today will either validate the entire oncology pipeline or force a strategic rethink.
The company is not betting everything on pumitamig alone. Another candidate, gotistobart — a CTLA-4 antibody developed with OncoC4 — delivered encouraging signals at the European Lung Cancer Congress in March. In squamous lung cancer, the median overall survival had not been reached after a median follow-up of 14.5 months, compared with 10 months for docetaxel. The 12-month survival rate stood at 63.1% versus 30.3%, yielding a hazard ratio for death of 0.46. Pivotal Phase 3 interim results are expected later this year; primary data collection for that study concludes in June.
Behind the science, the numbers paint a stark financial picture. Revenue slumped to $138 million, while the net loss ballooned to $622 million as research spending surged to $651 million, fueled by investments in pumitamig, gotistobart, and the build-out of BioNTech China. The company is sticking to its 2026 revenue guidance of $2.3 billion to $2.6 billion, and a cash pile of approximately $19.6 billion — along with a $1 billion share buyback programme — provides a thick cushion. Yet the market remains unconvinced, with the stock down roughly 17% over the past 30 days.
Should investors sell immediately? Or is it worth buying BioNTech?
That caution is reflected in analyst divergences. J.P. Morgan maintains a "Hold" rating, but the broader consensus among 17 analysts is a "Buy", with a 12-month price target of $125.45. Morgan Stanley recently lifted its target to $126 and stayed "Overweight", while Truist upgraded the stock to "Strong Buy" and Jefferies reaffirmed its "Buy". The split underscores the binary nature of today's ASCO readout.
Meanwhile, the company is undergoing a deep operational overhaul that mirrors its clinical ambitions. BioNTech plans to cut around 1,860 jobs and close three manufacturing sites in Germany — in Idar-Oberstein, Marburg, and Tübingen — with annual cost savings of up to €500 million expected from 2029 onward. From the end of 2026, partner Pfizer will take over full commercial production of COVID-19 vaccines, freeing BioNTech to channel all resources into oncology.
The restructuring coincides with a change at the top. During the annual general meeting, CEO Ugur Sahin hinted that it might have been his last address as chairman of the board, signaling a pending leadership transition at a critical juncture.
BioNTech at a turning point? This analysis reveals what investors need to know now.
For now, all eyes are on the ASCO abstracts. Pumitamig's performance will determine whether BioNTech can shed its Covid-era skin and emerge as a legitimate force in cancer treatment. The stock's recent drift suggests the market is waiting for hard data before placing its next bet.
Ad
BioNTech Stock: New Analysis - 21 May
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
